Latest Biotechnology, Pharmaceutical and Healthcare News from BioPharma-Reporter

20:21 EST 15th January 2019 | BioPortfolio

Here are the most relevant search results for "BioPharma-Reporter" found in our extensive news archives from over 250 global news sources.

More Information about BioPharma-Reporter on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about BioPharma-Reporter for you to read. Along with our medical data and news we also list BioPharma-Reporter Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPharma-Reporter Companies for you to search.

Showing News Articles 1–25 of 340 from BioPharma-Reporter

Tuesday 15th January 2019

‘Not business as usual at FDA’: Only addressing immediate threats due to shutdown

The US FDA is faced with lapsed funding appropriations as the US government shutdown continues, causing the agency to focus on addressing immediate threats to consumer safety.

AZ to close two facilities in Colorado

The UK company will close two facilities in Boulder and Longmont eliminating 210 positions.

Sarepta signs plasmid supplier agreement after clinical trial hold

Sarepta signed a long-term agreement for the supply of plasmid DNA for its gene therapy program and the needs of any future programs.

Monday 14th January 2019

DuPont excipient could ‘double to triple’ biologics’ shelf life

DuPont has developed an excipient that could be more efficient and stable than current products on the market.

Friday 11th January 2019

Biosimilars in the US: Rising applications and approval rates

Biosimilar approvals in the US have increased by 600% and with biologic patent expiration dates approaching, biosimilar applications are on the rise as well.

Thursday 10th January 2019

Catalent to double biomanufacturing capacity with $200m investment

Catalent will use the funds to enlarge drug substance manufacturing and drug product fill/finish capacity.

‘An incredible opportunity’: Takeda signs immuno-oncology collaborations

Takeda entered multiple research collaborations for immuno-oncology and CAR-T therapies, an area of strategic focus for the company.

Novartis knocked back by UK on first-in-class migraine treatment

Novartis treatment for migraines is rejected by NICE on cost-effectiveness grounds, and on a lack of long-term data.

Wednesday 9th January 2019

BMS-Celgene deal: CEO looking to the ‘evolution’ of market with cell therapies

BMS' CEO explains that the deal will help the company to âparticipate in the growth and evolutionâ of oncology, spearheaded by cellular therapies.

From CAR-T to CAAR-T: Funding drives biotech into emerging space

Cabaletta Bio closed a $50m Series B funding enabling the company to develop further in the CAAR-T space.

Janssen offers $818m to access CRISPR tech

Janssen has licensed Locusâ CRISPR-Cas3 technology to target two bacterial pathogens for the development of treatments for infections.

Tuesday 8th January 2019

Fujifilm invests $112m on two fronts with new site and expansion

Fujifilm has launched an upgrade to its subsidiaries manufacturing capabilities, by increasing capacity by 50% at an existing facility and building an entirely new site for cell technology.

Sanofi and Regeneron restructure bispecifics discovery agreement in $462m deal

Sanofi and Regeneron updated their 2015 global immune-oncology discovery and development agreement to refocus drug discovery.

Bispecific discovery agreement restructured gives Sanofi I-O flexibility

Sanofi and Regeneron updated their 2015 global immune-oncology Discovery and Development Agreement to refocus drug discovery and give Sanofi more flexibility in advancing a pipeline.

Monday 7th January 2019

The impact of biosimilars in 2018: ‘Treating a third more people, at half the cost’

2018 saw an increase in the number of biosimilar approvals, and the expiry of patents on major products that allowed the entry of biosimilars across Europe.

Friday 4th January 2019

Biologics company sells shares, registers with SEC

Harpoon offers to sell shares of its common stock in its proposed IPO after registering a statement with the SEC while developing T-Cell engagers.

China boasts second domestically developed PD-1 approval

Eli Lilly and Innovent announced that their jointly developed anti-PD-1 drug gained approval in China, becoming the second domestically produced treatment of this type.

Thursday 3rd January 2019

Promising pipeline for cell and gene therapies

With nearly 300 cell and gene therapies in development, targeting more than 100 diseases, 2019 could be set to be a big year for cell and gene therapies.

Wednesday 2nd January 2019

Biotherapeutics companies to ‘achieve critical mass’ after merger

HJB and MabSpace merge, combining drug development, commercialization, and GMP manufacturing capabilities, to establish Transcenta.

Novartis makes acquisition to buildout CAR-T capabilities

Novartis will acquire French CDMO, CellforCure, to expand its cell and gene therapy manufacturing network.

Biologics CDMO buys Shire Massachusetts facility

Rentschler Biopharma will buy Shireâs development and manufacturing facility in Milton, Massachusetts, where the latter makes haemophilia A product, Obizur, for commercial production.

Wednesday 19th December 2018

MilliporeSigma and genOway enter CRISPR collaboration

genOway has acquired exclusive rights to MilliporeSigma's genome-editing patents to produce and sell new rodent models.

Alnylam settles ‘inherently unpredictable’ patent litigation over Onpattro

Alnylam settled its patent litigation with Silence Therapeutics, after an ongoing litigation regarding patent infringement of Silenceâs RNAi therapy.

Watch out for the ‘scale and speed’ of transformation in China, says Sanofi exec

Transformation in cell therapies is happening at an even faster rate than the US, suggests Christoph Heinemann of Sanofi.

Tuesday 18th December 2018

Pfizer wins EMA positive opinion for Avastin biosimilar

The EMA has recommended approval of Pfizerâs Zirabev, a proposed biosimilar to Rocheâs Avastin.

Quick Search


News Quicklinks